Showing 2131-2140 of 2314 results for "".
- VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridiahttps://modernod.com/news/veo-ophthalmics-to-support-the-masket-foundation-to-raise-awareness-of-aniridia/2477331/VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the
- Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Diseasehttps://modernod.com/news/acucela-provides-update-on-emixustat-phase-3-clinical-trial-in-patients-with-stargardt-disease/2477295/Acucela announced that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride in patients with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, and placebo-contro
- Adverum Reports New Interim Data from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-reports-new-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477288/Adverum Biotechnologies announced new interim clinical data from the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macu
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- Staar Surgical Announces the EVO Implantable Lens US Clinical Trial is Underwayhttps://modernod.com/news/staar-surgical-announces-the-evo-implantable-lens-us-clinical-trial-is-underway/2477273/Staar Surgical announced the first patient was implanted in the company’s US human clinical study for its EVO ICL family of lenses. The investigational study, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens,” will be conducted at more than a dozen ophthalmology
- Bausch Health and Clearside Biomedical Announce Publication of Pivotal Phase 3 Data on Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-publication-of-pivotal-phase-3-data-on-xipere/2477264/Bausch Health Companies and Clearside Biomedical announced that results from the randomized, controlled, double-masked phase 3 clinical trial (PEACHTREE study) of Xipere (triamcinolone acetonide suprachoroidal injectable suspension), have been published in Ophthalmology.1 Xiper
- AOA Receives Department of Justice Approval to Expand Group Purchasing Activities for Its AOAExcel Membershttps://modernod.com/news/aoa-receives-department-of-justice-approval-to-expand-group-purchasing-activities-for-its-aoaexcel-members/2477244/The Department of Justice (DOJ) announced January 15 that it will not challenge a proposal by the American Optometric Association to expand its group purchasing organization’s (GPO) activities to include the purchase of optometric products for resale to consumers, specifically eyeglass lenses, fr
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint-in-phase-2-mystic-trial-in-subjects-with-dry-eye-disease/2477225/Oyster Point Pharma announced positive topline results from its phase 2 MYSTIC study in dry eye disease. Results showed a statistically significant improvement in Schirmer’s score from baseline at Day 84 in both doses as compared to control.
- The American Optometric Association (AOA) Launches Nationwide Campaign to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-launches-nationwide-campaign-to-make-2020-the-year-of-the-eye-exam/2477227/The American Optometric Association (AOA) announced the official launch of the #2020EyeExam campaign to make eye health and vision care a national priority in 2020. The public awareness campaign underscores the importance of receiving an in-person comprehensive eye examination with an AOA doctor